5 Key Takeaways
-
1
The 48-month results from OAKS, DERBY, and GALE demonstrate the effectiveness of pegcetacoplan in treating geographic atrophy.
-
2
Continuous treatment with pegcetacoplan preserved approximately 1.5 disc areas of tissue in patients receiving monthly therapy.
-
3
Longer treatment duration correlates with increased efficacy, showing a 10% to 15% reduction in GA growth in the second two years.
-
4
Microperimetry results indicate a one-third risk reduction in central loci progression to absolute scotoma with extended therapy.
-
5
Safety data from GALE aligns with previous trials, showing no new safety signals and consistent real-world safety profiles.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
